Your session is about to expire
← Back to Search
Other
SNV1521 for Advanced Cancer
Phase 1
Recruiting
Research Sponsored by Synnovation Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Advanced or metastatic solid tumor malignancy
ECOG Performance Status 0 or 1
Must not have
Significant gastrointestinal disease
Liver dysfunction
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from first dose through last dose (up to 13 months)
Awards & highlights
Summary
"This trial is testing a new medicine called SNV1521 for people with advanced cancers. The researchers are trying to see if the medicine is safe, well-tolerated, and effective in treating solid
Who is the study for?
This trial is for people with advanced solid tumors that are measurable, who have tried other treatments without success or can't tolerate them. Participants should be relatively active and mobile (ECOG status 0 or 1) and expected to live more than three months.
What is being tested?
The study is testing SNV1521, a new medication for advanced cancers. It aims to determine the safety, tolerability, and effectiveness of SNV1521 by exploring different doses to find the best balance between efficacy and safety.
What are the potential side effects?
While specific side effects of SNV1521 aren't listed here, common side effects from cancer drugs may include nausea, fatigue, skin reactions, blood count changes leading to increased infection risk or bleeding tendencies.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My cancer has spread beyond its original location.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have a serious stomach or intestine condition.
Select...
I have liver problems.
Select...
I have active cancer spread to my brain or its coverings.
Select...
I have had cancer other than my current diagnosis in the last 2 years.
Select...
I have HIV with a low CD4+ count or detectable virus.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from first dose through last dose (up to 13 months)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from first dose through last dose (up to 13 months)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Safety of SNV1521
Tolerability of SNV1521
Trial Design
2Treatment groups
Experimental Treatment
Group I: Dose ExpansionExperimental Treatment1 Intervention
Group II: Dose EscalationExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Synnovation Therapeutics, Inc.Lead Sponsor
Share this study with friends
Copy Link
Messenger